Head-to-head evidence
Risperidone (Risperdal Consta) vs Ziprasidone
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Risperidone (Risperdal Consta)
Marketed by Johnson & Johnson
NCT00253136 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled trial with 458 participants, using change in a standard psychiatric symptom scale as the primary measure. The FDA product label for this pivotal trial reports that 47% of patients on the 25 mg dose showed a clinically meaningful improvement, compared with 17% on placebo.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
Ziprasidone
Marketed by Pfizer and partners
NCT00159770 · Phase 3 · completed
The study used randomization and active comparators but was open-label, with 290 participants, and its primary clinical endpoint was PANSS symptom change. No results are posted, so the primary endpoint cannot be classified as met or missed.
Next expected readout: February 2027 · NCT03781115 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Risperidone (Risperdal Consta)'s landscape · Ziprasidone's landscape